Immunomodulatory Effects of 3-hydroxy-3-methylglutaryl Coenzyme-A Reductase Inhibitors, Potential Therapy for Relapsing Remitting Multiple Sclerosis
Overview
Authors
Affiliations
This study characterized immunomodulatory targets of statins in humans and their potential for treatment of relapsing remitting multiple sclerosis (RR MS). Statins inhibited the proliferative response of mononuclear cells. Simvastatin, the statin with the strongest antiproliferative effect, inhibited IFN-gamma-induced expression of MHC class II DR on monocytes and decreased their antigen presenting capacity. As for T lymphocytes, it inhibited their activation and expression of the Th1 lineage differentiation markers. Simvastatin inhibited IFN-gamma, TNF-alpha, and IL-2 secretion, as well as the expression of T-bet, a transcription factor that regulates Th1 cell differentiation.
Blackstone J, Williams T, Nicholas J, Bordea E, De Angelis F, Bianchi A BMJ Open. 2024; 14(9):e086414.
PMID: 39284697 PMC: 11409264. DOI: 10.1136/bmjopen-2024-086414.
Huntemann N, Rolfes L, Pawlitzki M, Ruck T, Pfeuffer S, Wiendl H Drugs. 2021; 81(9):1031-1063.
PMID: 34086251 PMC: 8217012. DOI: 10.1007/s40265-021-01526-w.
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?.
Vasileiadis G, Dardiotis E, Mavropoulos A, Tsouris Z, Tsimourtou V, Bogdanos D Auto Immun Highlights. 2018; 9(1):9.
PMID: 30415321 PMC: 6230324. DOI: 10.1007/s13317-018-0109-x.
Statin treatment in multiple sclerosis: a systematic review and meta-analysis.
Pihl-Jensen G, Tsakiri A, Frederiksen J CNS Drugs. 2015; 29(4):277-91.
PMID: 25795002 DOI: 10.1007/s40263-015-0239-x.
Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals.
Rodriguez-Perea A, Montoya C, Olek S, Chougnet C, Velilla P J Immunol Res. 2015; 2015:762506.
PMID: 25759848 PMC: 4352479. DOI: 10.1155/2015/762506.